Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27251643 | 0.89 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1MITFSLC5A1SLC5A2 | |
| SCHEMBL19326955 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MITFSLC5A1SLC5A2 | |
| SCHEMBL18321355 | 0.87 | KCNMA1 (0.58) | SMN1; SMN2ALDH1A1MITFSLC5A1SLC5A2 | |
| SCHEMBL16840332 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1MITFSLC5A1SLC5A2 | |
| SCHEMBL16840324 | 0.83 | MAPT (0.45) | SMN1; SMN2ALDH1A1MITFMAPTUSP2 | |
| SCHEMBL18329220 | 0.74 | MAPT (0.40) | SMN1; SMN2ALDH1A1MAPTL3MBTL1MAPK1 | |
| SCHEMBL19783798 | 0.73 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1MAPTL3MBTL1MAPK1 | |
| SCHEMBL29848981 | 0.73 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1MAPTL3MBTL1MAPK1 | |
| SCHEMBL27251644 | 0.72 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1MITFSLC5A1SLC5A2 | |
| SCHEMBL18412397 | 0.71 | MAPT (0.47) | SMN1; SMN2ALDH1A1MITFMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| WO-2015095783-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | SMN1; SMN2 688/4885ALDH1A1 1862/4885MITF 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.